ITOS News and Press, iTeos Therapeutics Inc. From 07/08/21

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

Kanizphoto/iStock via Getty Images iTeos Therapeutics ([[ITOS]] -2.9%) is trading lower after posting a record one-day gain yesterday in reaction to a collaboration with GlaxoSmithKline to jointly develop and commercialize anti-TIGIT antibody EOS-448. In addition to $625M as an upfront p...

peshkov/iStock via Getty Images Bitcoin (BTC-USD) received a boost on Monday thanks to comments from a couple of heavy hitters. Both Elon Musk and Paul Tudor Jones made remarks that goosed the cryptocurrency. Investors got some macro insight from a couple of top minds in the financial industr...

Shares of iTeos Therapeutics (NASDAQ: ITOS) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (NYSE: GSK) to co-develop an experimental cancer treatment known as EOS-448. EOS-448 is a monoclonal antibody treatment for patients with cancer. It's curr...

Gainers: Enochian Biosciences ENOB +127%, RAPT Therapeutics RAPT +101%, iTeos Therapeutics ITOS +37%, Novan NOVN +30%, Anavex Life Sciences AVXL +23%.Losers: Avenue Therapeutics ATXI -39%, Inhibikase Therapeutics (IKT) -21%, ...

Compugen (CGEN) jumped 5.3% on some takeover speculation following GlaxoSmithKline's (GSK) agreement with iTeos Therapeutics (ITOS) to jointly develop and commercialize EOS-448 an anti-TIGIT monoclonal antibody currently undergoing Phase 1 studies as a potential cancer therapy....

Enochian Biosciences (ENOB) +143% on FDA acceptance of pre-IND request for potential HIV cure.MediaCo Holding (MDIA) +63%.iTeos Therapeutics (ITOS) +52%.Entasis Therapeutics Holdings (ETTX) +25%.Orphazyme A/S (ORPH) +23%.Luokung Technology (LKCO) +22%.Mereo BioPharma Group plc (MREO) +17...

JuSun/iStock via Getty Images iTeos Therapeutics (ITOS) has surged ~60.2% in the pre-market after announcing an agreement with GlaxoSmithKline (GSK) to jointly develop and commercialize EOS-448 an anti-TIGIT monoclonal antibody currently undergoing Phase 1 studies as a potential can...

EOS-448 is currently in phase I for advanced solid tumours with a randomised PD-1 combination study planned for 2022 iTeos to receive a $625 million upfront payment in addition to potential milestones, and royalty payments on ex-US sales GSK and iTeos will co-commercialise and sha...

Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor...